Reduction in the Risk of Major Adverse Cardiovascular Events With Apabetalone, a Bet Protein Inhibitor, in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the Betonmace Trial-MedSci.cn

Reduction in the Risk of Major Adverse Cardiovascular Events With Apabetalone, a Bet Protein Inhibitor, in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the Betonmace Trial

Schwartz, GG; Nicholls, SJ; Ginsberg, H; Johansson, J; Kalantar-Zadeh, K; Kulikowski, E; Toth, PP; Wong, N; Sweeney, M; Ray, KK

CIRCULATION, 2020; 142 ():